BlossomHill Therapeutics, Inc. (BLSM)

Chart not available yet

Data will show when the stock starts trading.

Market Cap	n/a
Revenue (ttm)	n/a
Net Income	-71.09M
EPS	n/a
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About BLSM

BlossomHill Therapeutics is a clinical-stage biopharmaceutical company applying our intentional, chemistry-based approach to develop innovative small molecule medicines that address significant unmet medical needs in cancer treatment. With each of our programs, we combine a deep understanding of disease and protein dynamics with our structure-based rational drug design expertise to identify the specific structural liabilities that limit existing therapies or approaches, and then design novel chemical scaffolds to directly address these limitati...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Employees: 63
• Stock Exchange: NASDAQ
• Ticker Symbol: BLSM
• Website: https://bhtherapeutics.com/

Financial Performance

Financial numbers in USD

Data Source: SEC filings Last updated: Jul 23, 2026

The data for this page was gathered manually by the Stock Analysis team, from official company filings available on SEC.gov.

Data Sources Report a data error